Research Article

Impairments of Visuospatial Attention in Children with Unilateral Spastic Cerebral Palsy

Table 2


SubjectAgeTotal omitted stars ()Ogden figure copy (score)Line bisection: average error (%)Proprioceptive pointing: average error (%)MACS (level)GMFCS (level)Lesion timingLesion sideLesion localizationAntiepileptic drugOphthalmologic deficits

154120.8−3.011PWM/PVLLeftcNANA
25164−8.73.321GMIRighteNANA
3630−18.5−4.321GMIRightaNANA
46274−0.12.511No MRIRightaNANA
5600−0.53.012GMILeftcNANA
66124−1.51.022GMILeftczO
769338.54.021GMILeftdNANA
86106.20.811PWM/PVLLeftfNANA
9682−3.21.821GMILeftfNANA
10600−1.50.322PWM/PVLLeftgNAO
1164116.0−1.031PWM/PVLLeftgNANA
12641432.91.721GMILeftgNANA
1363219.07.511PWM/PVLLeftgNANA
146313.027.021PWM/PVLRightgNANA
1561111.86.011PWM/PVLRightgNANA
167217.90.321GMILeftbNAO
177106.5−5.821GMILeftbNANA
1875119.4−5.521GMILeftcNANA
197109.52.521PWM/PVLLeftcNANA
2078214.86.822GMILeftdNAH/St
217113.20.521GMILeftdNANA
2276112.02.521GMILeftdNANA
237528.51.321GMILeftfNANA
24720−10,8−0,521MCDRightfzNA
25700−4.25.311MCDRightfNANA
2675213.31.021PWM/PVLLeftgNAExo/M-1
277624.5−0.321No MRILeftgNANA
28721−10.1−4.322GMIRightgNAQ/Exo-R Hyper
29790−7.24.011PWM/PVLRightgNAO
30741−8.76.731PWM/PVLRightgNANA
317254−30.60.021MCDRightgNANA
32760−3.9−0.821PWM/PVLRightgNANA
33801−4.8−3.521GMIRightbNASt/Eso
348142−17.8−0.721PWM/PVLRightcNANA
35800−7.1−0.521GMIRightcNANA
36800−2.75.031GMILeftdNANA
37841−6.36.321GMIRightfNANA
3880013.8−1.022GMILeftgNANA
398003.70.311PWM/PVLLeftgNANA
408004.51.811PWM/PVLLeftgNANA
41891−9.1−15.011PWM/PVLRightgNANA
428312−5.411.321GMIRightgNANA
439708.04.331GMILeftcNANA
449109.51.031GMILeftcNANA
45901−5.10.531No MRILeftcNANA
469227.54.031GMILeftdNANA
47940−0.4−0.422MCDLeftezO
489001.21.321PWM/PVLLeftgNANA
4995011.5−0.821PWM/PVLLeftgNANA
50102228.04.822GMILeftdyNA
511001−0.6−1.822GMIRighteyNA
521000−0.9−0.822PWM/PVLLeftgNAO
531020−1.36.021PWM/PVLLeftgNANA
5410208.21.311PWM/PVLLeftgNANA
551110−2.6−0.521No MRILeftaNANA
5611306.41.811GMILeftbNANA
571100−2.80.011GMIRightcNAO
581110−8.5−4.021GMIRightdNANA
591100−1.02.322PWM/PVLRightgNANA
601110−5.2−1.821PWM/PVLRightgNASt/L-Hyper/M1/M-2
611110−11.41.821PWM/PVLRightgNANA
6212132−0.6−1.521PWM/PVLLeftaNANA
631212−7.6−1.821No MRIRightaNANA
641200−0.11.321MCDLeftfNANA
6512002.3−3.721GMILeftfNANA
6612402.0−4.011PWM/PVLLeftgNANA
671200−6.8−1.711MCDRightgNANA
68130115.89.331GMILeftcNANA
6913106.30.021PWM/PVLRightgNANA
701400−2.60.021PWM/PVLRightgNANA
7115107.60.021No MRILeftay; xNA
7215003.21.521PWM/PVLLeftgNANA
731600−6.8−3.521PWM/PVLRightdNAH/St/ESO/M-3
741701−12.81.021PWM/PVLRightcNANA
7517000.8−4.731GMILeftfNANA

Lesion timing: MCD: brain malformation; PWM/PVL: periventricular white matter lesion; GMI: cortical/subcortical lesion. Lesion localization: a: no MRI; b: subcortical and cortical lesions of frontal/parietal/temporal areas; c: subcortical and cortical lesions of frontal/parietal/temporal areas and insula; d: subcortical and cortical lesions of frontal/parietal/temporal/occipital areas and insula; e: subcortical and cortical lesions of parietal/occipital/temporal lesion; f: subcortical and cortical lesions of parietal/temporal lesions; g: subcortical without cortical lesions. Antiepilectic drug: z: valproate; y: carbamazepine; x: lamotrigine. Ophthalmologic deficit: NA: no available data; O: no deficit; H: hemianopsia; Q: quadranopsia; St: stereoscopic vision deficit; Exo: exotropia; Eso: esotropia; R Hyper: right hypertropia; L Hyper: left hypertropia; M-1: eye motility deficit in the left eye; M-2: eye motility deficit in the right eye; M-3: presence of gaze-evoked nystagmus.